INMB

8.03

2.29% 0.18

Dopo l'orario di chiusura: 8.03

Inmune Bio Inc (INMB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$7.85

Aprire:

$7.74

Volume 24 ore:

232.41K

Relative Volume:

0.66

Capitalizzazione di mercato:

$178.04M

Reddito:

$155.00K

Utile/perdita netta:

$-30.01M

Rapporto P/E:

-4.8084

EPS:

-1.67

Flusso di cassa netto:

$-11.98M

1 W Prestazione:

-6.52%

1M Prestazione:

+0.12%

6M Prestazione:

+17.57%

1 anno Prestazione:

-32.06%

Intervallo 1D:

$7.30

$8.135

Intervallo di 1 settimana:

$7.30

$8.69

Portata 52W:

$4.32

$13.30

Inmune Bio Inc Stock (INMB) Company Profile

Nome

Inmune Bio Inc

Settore

Healthcare (1185)

Industria

Biotechnology (679)

Telefono

(858) 964-3720

Indirizzo

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Dipendente

Cinguettio

@INmuneBio

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

INMB's Discussions on Twitter

Confronta INMB con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
INMB Inmune Bio Inc	8.03	178.04M	155.00K	-30.01M	-11.98M	-1.67
VRTX Vertex Pharmaceuticals Inc	479.79	123.21B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	698.74	76.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	624.67	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.75	31.94B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	271.80	29.00B	3.32B	-860.46M	-1.04B	-8.32

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-01-28	Iniziato	Rodman & Renshaw	Buy
2024-10-21	Iniziato	Alliance Global Partners	Buy
2024-09-27	Iniziato	Raymond James	Outperform
2024-08-22	Iniziato	Scotiabank	Sector Outperform
2023-06-01	Iniziato	Robert W. Baird	Outperform
2022-05-24	Downgrade	B. Riley Securities	Buy → Neutral
2021-07-07	Reiterato	Maxim Group	Buy
2021-04-21	Iniziato	B. Riley Securities	Buy
2021-01-22	Reiterato	Maxim Group	Buy
2020-09-01	Iniziato	BTIG Research	Buy
2020-07-15	Reiterato	H.C. Wainwright	Buy

Mostra tutto

Inmune Bio Inc Borsa (INMB) Ultime notizie

Feb 27, 2025

Is INmune Bio (NASDAQ:INMB) A Risky Investment? - Simply Wall St

Feb 27, 2025

Feb 24, 2025

INmune Delivers Impressive 100% Gain In Just 3 MonthsIs There More Room To Run? - RTTNews

Feb 24, 2025

Feb 23, 2025

Learn to Evaluate (INMB) using the Charts - Stock Traders Daily

Feb 23, 2025

Feb 21, 2025

INmune Bio, Inc. to Host Earnings Call - ACCESS Newswire

Feb 21, 2025

Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% - Yahoo Finance

Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter

Feb 20, 2025

Feb 18, 2025

INmune Bio, Inc. (NASDAQ:INMB) Sees Significant Growth in Short Interest - Defense World

Feb 18, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Analysts - Defense World

Feb 18, 2025

Feb 16, 2025

INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Maxim Group Analyst Says - MarketBeat

Feb 16, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Brokerages - Defense World

Feb 16, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Average Price Target from Brokerages - MarketBeat

Feb 16, 2025

Feb 14, 2025

INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Scotiabank Analyst Says - MarketBeat

Feb 14, 2025

Feb 13, 2025

Raymond James raises INmune Bio stock target to $23 By Investing.com - Investing.com Nigeria

Feb 12, 2025

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer - The Manila Times

Feb 12, 2025

INmune Bio Inc. Reports Safe Phase 1 Results for INKmune™ in mCRPC, Opens Phase 2 Enrollment - Nasdaq

Feb 12, 2025

Inmune Bio’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating - TipRanks

Feb 12, 2025

INmune Bio’s CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com Nigeria

Feb 12, 2025

Scotiabank raises INmune Bio stock target to $23 on new therapy - MSN

Feb 12, 2025

INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc. (NASDAQ: INMB) submitted an 8-K form to the Securities and Exchange Commission, revealing that the company had developed an Investor Presentati - Defense World

Feb 12, 2025

Feb 11, 2025

INmune Bio's CORDStrom shows promise in RDEB treatment - MSN

Feb 11, 2025

Market Insight: INmune Bio Inc (INMB)’s Notable Drop, Closing at 9.12 - The Dwinnex

Feb 11, 2025

Scotiabank raises INmune Bio stock target to $23 on new therapy By Investing.com - Investing.com South Africa

Feb 11, 2025

Feb 10, 2025

BLA Submission Planned for CORDStrom in RDEB - MD Magazine

Feb 10, 2025

Inmune Bio Secures License Agreement for CORDStrom Data - TipRanks

Feb 10, 2025

INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe -February 10, 2025 at 10:26 am EST - Marketscreener.com

Feb 10, 2025

Inmune Bio Completes Phase 2 Trial for CORDStrom - TipRanks

Feb 10, 2025

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - Markets Insider

Feb 10, 2025

INmune Bio's CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com South Africa

Feb 10, 2025

INmune Bio (INMB) to Submit FDA Biologics License Application Seeking Approval of CORDStrom - StreetInsider.com

Feb 10, 2025

Feb 07, 2025

Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Expands By 7.0% - MarketBeat

Feb 07, 2025

Feb 05, 2025